The word hepatitis comes from the Ancient Greek word hepar (root word hepat) meaning ‘liver’, and the Latin itis meaning inflammation. Hepatitis means injury to the liver with inflammation of the liver cells.
What is the liver?
The liver is the largest gland in the human body. It weighs approximately 3 lb (1.36 kg). It is reddish [...]
Oxidative stress describes the state level of oxidative damage in a cell, tissue or organ, caused by reactive oxygen species. Alcohol induces oxidative stress in the liver resulting in an imbalance between oxidants and anti-oxidants. Increased reactive oxygen species (ROS) production and glutathione (GSH) depletion, lead to abnormal breakdown of fat molecules (i.e., lipid peroxidation). [...]
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, announced that it has enrolled the first patient in a disease-directed Phase II clinical trial of IMC-1121B to treat patients with advanced hepatocellular carcinoma (liver cancer). IMC-1121B, an anti-vascular endothelial growth factor receptor-2 (VEGFR-2) monoclonal antibody, [...]
HBV is tiny. The genome of this virus is a partial double stranded circle. When made fully double stranded, this genome carries about 3000 base pairs, compared to 200 kilo base pairs of the genome of the smallpox virus. These 3000 base pairs encode an envelope protein, a core protein, a polymerase essential for virus [...]
Arbios Systems, Inc. (OTC Bulletin Board: ABOS) announced that the Company has received conditional approval from the U.S. Food and Drug Administration (“FDA”) of an Investigational Device Exemption (“IDE”) to begin the pivotal clinical trial for SEPET(TM), Arbios’ extracorporeal (outside the body) artificial liver assist device for blood purification of chronically ill patients suffering from [...]
Geisinger Health System and Celera (NYSE:CRA), an Applera Corporation business, has announced that they have entered into a research collaboration with the aim of developing a diagnostic assay for the increased risk of non-alcoholic steatohepatitis (NASH). The collaboration will evaluate Celera’s numerous genetic findings in liver diseases, including the Cirrhosis Risk Score™, in the Geisinger [...]
 |  |  |  |  |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| By N2H | |||||||||||||